Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

Alicia Leon-Castillo,Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Helen Mackay,Alexandra Leary,Hans W. Nijman,Naveena Singh,Pamela M. Pollock,Paul Bessette,Anthony Fyles,Christine Haie-Meder,Vincent T.H.B.M. Smit,Richard J. Edmondson,Hein Putter,Henry C Kitchener,Emma J. Crosbie,Marco de Bruyn,Remi A. Nout,Nanda Horeweg,Carien L. Creutzberg,Tjalling Bosse

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

2020

PURPOSEThe randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and...

Keywords:

adjuvant chemoradiotherapy
Adjuvant therapy
Oncology
molecular classification
Medicine
Endometrial cancer
Internal medicine
radiotherapy alone
adjuvant chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations